Nektar Therapeutics (NKTR) Stock Price, Quote & News

Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 482 5300

Fax: 415 339 5300

Website: www.nektar.com

Address:

455 Mission Bay Boulevard South, San Francisco, United States

Kayjafri Jul. 7 at 7:53 PM

$NKTR So many shorts here, will be fuel for next squeeze!

0 · Reply

Quantumup Jul. 7 at 6:36 PM

Citi reiterated $APGE Buy-$95 and said "We see today's Phase 2a data for APG777 ('777) in atopic dermatitis (AD) as a major de-risking event for the program." $REGN $LLY SNY $CRVS $NKTR Citi went on to say:

0 · Reply

victor32 Jul. 7 at 6:29 PM

$NKTR i wonder when is the next offering

1 · Reply

BigTe Jul. 7 at 6:16 PM

$NKTR Congrats to those who bought Puts when it was $38

1 · Reply

george4it Jul. 7 at 5:30 PM

$NKTR Added another 400 shares today at 23

0 · Reply

Tradeislife Jul. 7 at 5:19 PM

$NKTR teens incoming.

0 · Reply

Lionhearts_Eng Jul. 7 at 5:09 PM

$NKTR $16 is next

0 · Reply

AnAverageDude Jul. 7 at 5:07 PM

$NKTR the vastly majority of bulls now holding bags. Yikes.

0 · Reply

nesanmano Jul. 7 at 4:45 PM

$NKTR guys, the whole market is red

1 · Reply

PenDayo Jul. 7 at 4:32 PM

$NKTR

0 · Reply

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 1, 2025, 7:17 AM EDT - 6 days ago

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Jun 30, 2025, 4:02 PM EDT - 7 days ago

Nektar Therapeutics Announces Proposed Public Offering

Jun 27, 2025, 8:45 AM EDT - 10 days ago

Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg

Jun 25, 2025, 1:42 PM EDT - 12 days ago

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?

Jun 24, 2025, 1:20 PM EDT - 13 days ago

Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?

Jun 24, 2025, 7:35 AM EDT - 13 days ago

Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial

Jun 24, 2025, 7:30 AM EDT - 13 days ago

REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

Jun 23, 2025, 4:30 PM EDT - 13 days ago

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025

Jun 11, 2025, 3:13 PM EDT - 26 days ago

Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC

Jun 10, 2025, 5:26 PM EDT - 26 days ago

AMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and Provenance

May 13, 2025, 5:00 PM EDT - 7 weeks ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 10:08 PM EDT - 2 months ago

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:15 PM EDT - 2 months ago

Nektar Therapeutics Reports First Quarter 2025 Financial Results

May 1, 2025, 6:00 PM EDT - 2 months ago

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

Mar 20, 2025, 6:00 PM EDT - 3 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 12, 2025, 8:00 PM EDT - 4 months ago

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 4:15 PM EDT - 4 months ago

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 6:00 PM EST - 4 months ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Feb 26, 2025, 7:00 AM EST - 4 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Feb 24, 2025, 7:00 AM EST - 4 months ago

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

Feb 24, 2025, 7:00 AM EST - 4 months ago

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Feb 10, 2025, 7:00 AM EST - 5 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Jan 10, 2025, 7:00 AM EST - 6 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

$Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting$